<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although an activating mutation of Ras is commonly observed in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), the role of Ras in the natural history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> remains largely unknown </plain></SENT>
<SENT sid="1" pm="."><plain>We prospectively studied efficiency and tolerance of lonafarnib, a compound able to inhibit Ras signalling pathway through an inhibition of <z:chebi fb="0" ids="24017">farnesyl</z:chebi> transferase, in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or secondary <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (sAML) </plain></SENT>
<SENT sid="2" pm="."><plain>Lonafarnib was administered orally at a dose of 200 mg twice daily for three courses of 4 weeks (separated by 1 to 4 weeks without treatment) </plain></SENT>
<SENT sid="3" pm="."><plain>Sixteen patients were included: FAB/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> (n = 10), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB-T</z:e> (n = 2), sAML (n = 2) and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>; n = 2); WHO/<z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e> (n = 4), <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e> (n = 5), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (n = 5), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> (n = 2) </plain></SENT>
<SENT sid="4" pm="."><plain>Median age was 70 (53-77) years </plain></SENT>
<SENT sid="5" pm="."><plain>The karyotype was complex or intermediate in 11 patients, and the International Prognostic Scoring Systems (IPSS) risk groups were low in two patients, INT-1 in one patient, INT-2 in four patients and high in six patients (unknown or not applicable in three patients) </plain></SENT>
<SENT sid="6" pm="."><plain>Among the 14 patients tested, five had Ras mutations in codons 12, 13 or 61 of N-Ras, K-Ras or H-Ras </plain></SENT>
<SENT sid="7" pm="."><plain>One patient was excluded of the analysis for protocol violation, and 15 patients were assessable for tolerance </plain></SENT>
<SENT sid="8" pm="."><plain>Gastrointestinal toxicities (diarrhoea, <z:hpo ids='HP_0002018'>nausea</z:hpo> and <z:hpo ids='HP_0002039'>anorexia</z:hpo>) and <z:e sem="disease" ids="C0854467" disease_type="Disease or Syndrome" abbrv="">myelosuppression</z:e> were the major side effects </plain></SENT>
<SENT sid="9" pm="."><plain>Other toxicities included <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, <z:mp ids='MP_0002899'>fatigue</z:mp>, increase of liver enzymes, <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> and <z:hpo ids='HP_0000988'>skin rash</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>One patient died of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, and the treatment was stopped in one other who developed <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Doses were reduced in <z:hpo ids='HP_0000001'>all</z:hpo> but one patient treated with more than one course of <z:chebi fb="0" ids="24017">farnesyl</z:chebi> transferase inhibitor </plain></SENT>
<SENT sid="12" pm="."><plain>Responses were assessable in 12 patients </plain></SENT>
<SENT sid="13" pm="."><plain>A partial response in one sAML patient and a very transient decrease of blast cell count with normalisation of karyotype in one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patient were observed </plain></SENT>
<SENT sid="14" pm="."><plain>No relation between improvement of marrow parameters and detected Ras mutations was observed </plain></SENT>
<SENT sid="15" pm="."><plain>Lonafarnib alone, administered following our schedule, has shown limited activity in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>Gastrointestinal and haematological toxicities appear the limiting toxicity in this population of patients </plain></SENT>
</text></document>